Company intelligence / Profile preview

NeuroX

Geneva, Switzerland

Ownership: Private
Development stage: Other

Overview

NeuroX (successor to MindMaze) markets CE-marked, FDA-listed neurotherapeutics delivered via a digital/AI-driven platform for motor and cognitive rehabilitation. Its device/software suite is deployed commercially in 250+ clinics globally, covers multiple neurological indications, and is US-reimbursed (CAT-3 code). Clinical and real-world data demonstrate improved outcomes in stroke, Parkinson's, and aging populations, with an R&D pipeline for adjacent CNS diseases. CHF 350M invested for robust clinical/data foundation.[1][2][3]

Therapeutic areas: OtherNeurology
Modalities: DeviceSoftwareDigital therapeuticWearableAI-driven therapy
Industry: Digital Health Medical Devices

Partnerships

Multiple leading pharmaceutical companies (unnamed, for combined digital/pharma trials)

Beyond the preview

Go deeper on NeuroX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroX.

Explore the full profile